<DOC>
	<DOCNO>NCT01754402</DOCNO>
	<brief_summary>This study design phase I-II , open label , dose find study . Study treatment follow , 28 day cycle : - Pomalidomide : daily orally ( PO ) dose day 1-21 , every 28 day - Bendamustine : intravenously ( IV ) dose day 1 , every 28 day - Dexamethasone : weekly PO IV dose day 1 , 8 , 15 , 22 . After complete 6 cycle treatment , dexamethasone may decrease 20mg per investigator discretion . After complete 12 cycle treatment , patient proceed maintenance phase study . Patients receive Pomalidomide day 1-21 , every 28 day dexamethasone day 1 , 8 , 15 , 22 every 28 day time progression .</brief_summary>
	<brief_title>Bendamustine + Pomalidomide + Dex R/R Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY ENDPOINTS : Phase I • Determination MTD combination therapy Phase II : • Response rate ( CR+PR ) SECONDARY ENDPOINTS : - Overall Response ( SD , MR , PR , VGPR , CR , sCR ) - Progression Free Survival ( PFS ) - Time Progression ( TTP ) - Time next therapy A total 56 patient may enrol study : Dose escalation phase : Up 24 subject ; Dose expansion phase : Up maximum 38 patient treated maximum tolerate dose ( MTD ) . Study treatment administer start Cohort 1 four sequential cohort , 3-6 patient cohort . A standard 3+ 3 dose escalation schedule use . A minimum 3 patient enter within cohort , expand 6 patient dose limit toxicity ( DLTs ) observe , determine MTD . Once MTD reach , additional patient enrol MTD level . EVALUATION : - For toxicity : 1 cycle ( All patient consider evaluable toxicity unless complete first cycle therapy due withdrawal consent disease progression . ) - For efficacy : 2 cycle Intended treatment duration : Patients continue protocol long receive clinical benefit remove disease progression ( investigator 's discretion patient may treat one cycle progression note confirm progression ) , adverse event/unacceptable toxicity side effect , withdrawal consent . A DLT define follow occur first treatment cycle ( 28 day ) judge investigator least possibly relate study therapy : Hematologic : - Febrile neutropenia ( ANC &lt; 1.0x109/L ) fever 38.5 C. Subjects enter study low count ( ANC &lt; 1.0x109/L ) due &gt; 5030 % * marrow involvement evaluate portion DLT definition . - Grade 4 neutropenia ( ANC &lt; 0.5x109/L ) 7 day despite GCSF support . Subjects enter study low count ( ANC &lt; 1.0x109/L ) due &gt; 5030 % * marrow involvement evaluate portion DLT definition . - Grade 4 thrombocytopenia ( platelet count &lt; 25.0x109/L ) last &gt; 7 day despite dose delay . Subjects enter study low count ( platelet &lt; 50.0x109/L ) due &gt; 5030 % * marrow involvement evaluate portion DLT definition . - Grade 3-4 thrombocytopenia associate bleed - Any hematologic toxicity require dose reduction within Cycle 1 - Inability receive Day 1 dose Cycle 2 due drug relate toxicity persist Cycle 1 great 14 day Non-hematologic : - Any &gt; Grade 3 toxicity determine Investigator related pomalidomide bendamustine ( exception thrombotic event note ) . - &gt; Grade 3 nausea , vomit , diarrhea , despite use maximal antiemetic/antidiarrheal therapy - &gt; Grade 3 neuropathy pain - &gt; Grade 3 venous thromboembolic event . - Any Grade 4 rash relate agent consider DLT . - A Grade 3 rash relate agent resolve &lt; Grade 2 within 10 day period despite steroid therapy consider DLT . - If event attribute progressive disease , count DLT . - Any non-hematologic toxicity require dose reduction within Cycle 1 - Delay ability receive Day 1 dose Cycle 2 due drug relate toxicity persist Cycle 1 great 14 day</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must meet follow inclusion criterion eligible enroll study . 1 . Cytopathologically histologically confirm diagnosis multiple myeloma 2 . Relapsed refractory recent therapy ( i.e . &lt; 25 % response , progression therapy within 60 day completion ) . 3 . Refractory prior lenalidomide therapy ( i.e . history progression therapy use full maximally tolerate dose lenalidomide &gt; /= two cycle ) . 4 . Measurable disease : Serum M protein &gt; 0.5 g/dL Urine Bence Jones protein &gt; 200 mg/24 hr Elevated Free Light Chain per International Myeloma Working Group ( IMWG ) criterion , abnormal ratio 5 . Evidence progression/relapse 6 . Over 18 7 . Life expectancy 3 month 8 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 9 . Total bilirubin &lt; 2 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN 10 . Serum creatinine &lt; 3 mg/dL 11 . • Absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L &lt; 1.0 x 109/L &gt; 0.75 due &gt; 30 % * marrow involvement ( without granulocyte granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) &gt; 1 week pegylated GCSF &gt; 2 week ) Hemoglobin &gt; 8 g/dL Platelet count &gt; 75.0 x 109/L &lt; 75.0 x 109/L &gt; 50.0 x 109/L due &gt; 30 % * marrow involvement ( without platelet transfusion &gt; 1 week ) Transfusions allow clinically indicated 12 . Agree take enteric coat aspirin 81 mg daily 13 . Consent 14 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test abstain sex begin TWO acceptable method birth control &gt; 28 day pomalidomide dose , agree ongoing pregnancy test . 15 . Male patient must abstain sex use latex condom donate sperm take pomalidomide 1 week stop drug . 16 . Register POMALYST REMS™ comply requirement . EXCLUSION CRITERIA : 1 . Patients know sensitivity immunomodulatory drug ( IMiDs ) 2 . Use experimental drug therapy within 21 day studyrelated drug therapy . 3 . Exposure chemotherapy steroid within 14 day studyrelated drug therapy . 4 . Prior use pomalidomide . 5 . Radiation therapy within 14 day screen . 6 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) . 7 . Plasma cell leukemia . 8 . Waldenström 's macroglobulinemia . 9 . Major surgery within 21 day prior first dose . 10 . Pregnant lactating female . 11 . Congestive heart failure , symptomatic ischemia , conduction abnormality uncontrolled myocardial infarction last six month . 12 . Uncontrolled hypertension 13 . Acute active infection require systemic antibiotic , antiviral , antifungal within 14 day prior first dose . 14 . Active treatment intervention malignancy need active treatment within 8 month start study treatment . 15 . Serious psychiatric medical condition interfere treatment 16 . Significant neuropathy ( Grade 3 , Grade 4 ) first dose and/or within 14 day enrollment 17 . Contraindication require concomitant drug 18 . Patients primary systemic amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>